Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2014

Study Completion Date

July 16, 2016

Conditions
Cervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell CarcinomaEndometrial Clear Cell CarcinomaEndometrial Papillary Serous CarcinomaStage I Endometrial CarcinomaStage IB Cervical CancerStage II Endometrial CarcinomaStage IIA Cervical CancerStage IIB Cervical CancerStage III Cervical CancerStage III Endometrial CarcinomaStage IVA Cervical Cancer
Interventions
RADIATION

fludeoxyglucose F 18

Undergo FDG PET/CT

PROCEDURE

positron emission tomography

Undergo FDG PET/CT

PROCEDURE

computed tomography

Undergo FDG PET/CT

DRUG

ferumoxtran-10

Undergo femoxtran-10 MRI

PROCEDURE

magnetic resonance imaging

Undergo femoxtran-10 MRI

PROCEDURE

diagnostic lymphadenectomy

Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy

PROCEDURE

lymph node biopsy

Undergo pelvic and abdominal lymph node biopsy

Trial Locations (33)

10029

Mount Sinai Medical Center, New York

10065

Weill Medical College of Cornell University, New York

10461

Montefiore Medical Center-Einstein Campus, The Bronx

11718

Island Gynecologic Oncology, Brightwaters

19111

Fox Chase Cancer Center, Philadelphia

28203

Carolinas Medical Center, Charlotte

30912

Georgia Regents University Medical Center, Augusta

34239

Sarasota Memorial Hospital, Sarasota

37232

Vanderbilt-Ingram Cancer Center, Nashville

44106

Case Western Reserve University, Cleveland

45267

University of Cincinnati, Cincinnati

48201

Wayne State University/Karmanos Cancer Institute, Detroit

55905

Mayo Clinic, Rochester

73104

University of Oklahoma Health Sciences Center, Oklahoma City

78234

Brooke Army Medical Center, Fort Sam Houston

90095

Jonsson Comprehensive Cancer Center, Los Angeles

University of California at Los Angeles Health System, Los Angeles

91342

Olive View-University of California Los Angeles Medical Center, Sylmar

97213

Providence Cancer Center -The Plaza, Portland

Providence Portland Medical Center, Portland

06050

The Hospital of Central Connecticut, New Britain

02114

Massachusetts General Hospital Cancer Center, Boston

07103

UMDNJ - New Jersey Medical School, Newark

02905

Women and Infants Hospital, Providence

G1R 2J6

CHUQ - Pavilion Hotel-Dieu de Quebec, Québec

060-8648

Hokkaido University Hospital, Sapporo

892-8580

Kagoshima City Hospital, Kagoshima City, Kagoshima

350-1298

Saitama Medical University International Medical Center, Saitama

700-712

Keimyung University-Dongsan Medical Center, Jung-Ku

110-744

Seoul National University Hospital, Seoul

135-720

Gangnam Severance Hospital, Seoul

138-736

Asan Medical Center, Seoul

139-706

Korea Cancer Center Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | Biotech Hunter | Biotech Hunter